Top

Skeletal Radiology

Published in:

Open Access 01-03-2018 | Scientific Article

Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?

Authors: Ömer Kasalak, Andor W. J. M. Glaudemans, Jelle Overbosch, Paul C. Jutte, Thomas C. Kwee

Published in: Skeletal Radiology | Issue 3/2018

Abstract

Objective

To determine and compare the value of ¹⁸F–fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) to blind bone marrow biopsy (BMB) of the posterior iliac crest in detecting metastatic bone marrow involvement in newly diagnosed Ewing sarcoma.

Materials and methods

This retrospective study included 20 patients with newly diagnosed Ewing sarcoma who underwent pretreatment FDG-PET/CT and a total of 38 blind BMBs (two unilateral and 18 bilateral) of the posterior iliac crest. FDG-PET/CT scans were evaluated for bone marrow involvement, both in the posterior iliac crest and other sites, and compared to blind BMB results.

Results

FDG-PET/CT was positive for bone marrow involvement in 7/38 posterior iliac crests, whereas BMB was positive in 5/38 posterior iliac crests. FDG-PET/CT and BMB results in the posterior iliac crest agreed in 36/38 cases (94.7%, 95% confidence interval [CI]: 82.7–98.5%). On a patient level, FDG-PET/CT was positive for bone marrow involvement in 4/20 patients, whereas BMB of the posterior iliac crest was positive in 3/20 patients. On a patient level, FDG-PET/CT and BMB results agreed in 19/20 patients (95.0%, 95% CI: 76.4–99.1%). The only discrepancies between FDG-PET/CT and BMB were observed in two BMBs of one patient. Both BMBs in this patient were negative, whereas FDG-PET/CT indicated bilateral posterior iliac crest involvement and also extensive bone marrow involvement elsewhere.

Conclusions

FDG-PET/CT appears to be a valuable method for metastatic bone marrow assessment in newly diagnosed Ewing sarcoma. The routine use of blind BMB of the posterior iliac crest should be reconsidered when FDG-PET/CT is available.

Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–46.CrossRefPubMed

Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425–30.CrossRefPubMed

Bain BJ. Bone marrow biopsy morbidity: review of 2003. J Clin Pathol. 2005;58(4):406–8.CrossRefPubMedPubMedCentral

Harrison DJ, Parisi MT, Shulkin BL. The role of 18F-FDG-PET/CT in pediatric sarcoma. Semin Nucl Med. 2017;47(3):229–41.CrossRefPubMed

Boellaard R, Delgado-Bolton R, Oyen WJ, et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.CrossRefPubMed

Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284–91.CrossRefPubMed

Biermann JS, Chow W, Reed DR, et al. NCCN guidelines insights: bone cancer, version 2.2017. J Natl Compr Cancer Netw. 2017;15(2):155–67.CrossRef

ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii113–23.CrossRef

http://www.euroewing.eu/clinical-trials/ee2012-trial. Accessed 12 Aug 2017.

10.

Newman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-d-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer. 2013;60(7):1113–7.CrossRefPubMed

11.

Adams HJ, de Klerk JM, Fijnheer R, Dubois SV, Nievelstein RA, Kwee TC. Effect of blind bone marrow biopsy on FDG-PET/CT interpretation of the posterior iliac crest in diffuse large B-cell lymphoma. Hematol Oncol. 2016;34(1):52–4.CrossRefPubMed

12.

Ulaner GA, Magnan H, Healey JH, Weber WA, Meyers PA. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed? AJR Am J Roentgenol. 2014;202(4):859–67.CrossRefPubMed

Title: Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?
Authors: Ömer Kasalak
Andor W. J. M. Glaudemans
Jelle Overbosch
Paul C. Jutte
Thomas C. Kwee
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Skeletal Radiology / Issue 3/2018
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI: https://doi.org/10.1007/s00256-017-2807-2

At a glance: The STEP trials

Springer Medicine

Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?

Abstract

Objective

Materials and methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

A 4-year-old with a non-tender dorsal phalangeal lump: diagnosis and discussion

Magnetic resonance imaging-based morphological and alignment assessment of the patellofemoral joint and its relationship to proximal patellar tendinopathy

MRI findings in bucket-handle tears of the triangular fibrocartilage complex

An uncommon variant of the Essex-Lopresti injury

Diffusion weighted imaging demystified: the technique and potential clinical applications for soft tissue imaging

Stener-like lesion of the lateral collateral ligament of the first metatarsophalangeal joint